These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 17964003)

  • 21. A diagnosis of Fabry gastrointestinal disease by chance: a case report.
    Feriozzi S; Torre ES; Ranalli TV; Cardello P; Morrone A; Ancarani E
    Eur J Gastroenterol Hepatol; 2007 Feb; 19(2):163-5. PubMed ID: 17273003
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fabry disease: the need to stratify patient populations to better understand the outcome of enzyme replacement therapy.
    Germain DP
    Clin Ther; 2007; 29 Suppl A():S17-8. PubMed ID: 17580237
    [No Abstract]   [Full Text] [Related]  

  • 23. Fabry disease: dose matters.
    Warnock DG; Mauer M
    J Am Soc Nephrol; 2014 Apr; 25(4):653-5. PubMed ID: 24556355
    [No Abstract]   [Full Text] [Related]  

  • 24. Clinical trial for Fabry disease faces continuing hurdles.
    Silversides A
    CMAJ; 2009 Nov; 181(11):E251-2. PubMed ID: 19825933
    [No Abstract]   [Full Text] [Related]  

  • 25. Anderson-Fabry disease: a protean clinical behavior and a chance diagnosis.
    Amico L; Visconti G; Amato A; Azzolina V; Sessa A; Li Vecchi M
    J Nephrol; 2005; 18(6):770-2. PubMed ID: 16358237
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Agalsidase: a second look. With hindsight: full data challenge efficacy.
    Prescrire Int; 2003 Oct; 12(67):168-71. PubMed ID: 14619828
    [No Abstract]   [Full Text] [Related]  

  • 27. Fabrazyme--recombinant protein treatment for Fabry's disease.
    Barngrover D
    J Biotechnol; 2002 May; 95(3):280-2. PubMed ID: 12080957
    [No Abstract]   [Full Text] [Related]  

  • 28. Spotlight on agalsidase beta in Fabry disease.
    Keating GM; Simpson D
    BioDrugs; 2007; 21(4):269-71. PubMed ID: 17628124
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enzyme therapy for Fabry's disease: registered for success?
    Knebelmann B; Kurschat C; Thadhani R
    Lancet; 2009 Dec; 374(9706):1950-1. PubMed ID: 19959220
    [No Abstract]   [Full Text] [Related]  

  • 30. Shire drops 'emergency' Fabry's disease drug.
    Fox JL
    Nat Biotechnol; 2012 Jun; 30(6):478. PubMed ID: 22678371
    [No Abstract]   [Full Text] [Related]  

  • 31. Assessing antibodies to alpha-galactosidase A in Fabry disease.
    Richards SM
    Clin Ther; 2007; 29 Suppl A():S7-8. PubMed ID: 17580240
    [No Abstract]   [Full Text] [Related]  

  • 32. [Fabry disease].
    Jakubowska E; Ryba M; Hruby Z
    Przegl Lek; 2006; 63(4):218-9. PubMed ID: 17080745
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fabry disease during childhood: clinical manifestations and treatment with agalsidase alfa.
    Ramaswami U
    Acta Paediatr; 2008 Apr; 97(457):38-40. PubMed ID: 18339186
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Fatal outcome of a patient with Fabry disease in enzymatic treatment].
    Moyano MJ; del Toro N; Amor J; Milán JA
    Nefrologia; 2005; 25(2):207-8. PubMed ID: 15912661
    [No Abstract]   [Full Text] [Related]  

  • 35. Anderson-Fabry disease: enzyme replacement therapy.
    Leon-Mateos A; Fernández-Redondo V; Beiras A; Toribio J
    Acta Derm Venereol; 2004; 84(1):88-9. PubMed ID: 15040494
    [No Abstract]   [Full Text] [Related]  

  • 36. Fabry disease--whom to treat and when.
    Mehta A
    Clin Ther; 2008; 30 Suppl B():S43-4. PubMed ID: 18395136
    [No Abstract]   [Full Text] [Related]  

  • 37. Fabry disease: focus on cardiac manifestations and molecular mechanisms.
    Perrot A; Osterziel KJ; Beck M; Dietz R; Kampmann C
    Herz; 2002 Nov; 27(7):699-702. PubMed ID: 12439642
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enzyme replacement therapy with agalsidase beta in kidney transplant patients with Fabry disease: a pilot study.
    Mignani R; Panichi V; Giudicissi A; Taccola D; Boscaro F; Feletti C; Moneti G; Cagnoli L
    Kidney Int; 2004 Apr; 65(4):1381-5. PubMed ID: 15086478
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PR interval and the response to enzyme-replacement therapy for Fabry's disease.
    Waldek S
    N Engl J Med; 2003 Mar; 348(12):1186-7. PubMed ID: 12646684
    [No Abstract]   [Full Text] [Related]  

  • 40. [Fabry's disease in 2006: new treatment needs evaluation].
    Lidove O; Bekri S; Andrès E
    Presse Med; 2006 Jun; 35(6 Pt 1):933-5. PubMed ID: 16783249
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.